225 related articles for article (PubMed ID: 17196712)
1. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.
Darreh-Shori T; Kadir A; Almkvist O; Grut M; Wall A; Blomquist G; Eriksson B; Långström B; Nordberg A
Neurobiol Aging; 2008 Feb; 29(2):168-84. PubMed ID: 17196712
[TBL] [Abstract][Full Text] [Related]
2. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD.
Kadir A; Darreh-Shori T; Almkvist O; Wall A; Grut M; Strandberg B; Ringheim A; B Eriksson ; Blomquist G; Långström B; Nordberg A
Neurobiol Aging; 2008 Aug; 29(8):1204-17. PubMed ID: 17379359
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
5. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Nordberg A; Darreh-Shori T; Peskind E; Soininen H; Mousavi M; Eagle G; Lane R
Curr Alzheimer Res; 2009 Feb; 6(1):4-14. PubMed ID: 19199870
[TBL] [Abstract][Full Text] [Related]
6. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
Parnetti L; Chiasserini D; Andreasson U; Ohlson M; Hüls C; Zetterberg H; Minthon L; Wallin AK; Andreasen N; Talesa VN; Blennow K
Acta Neurol Scand; 2011 Aug; 124(2):122-9. PubMed ID: 20880294
[TBL] [Abstract][Full Text] [Related]
7. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
[TBL] [Abstract][Full Text] [Related]
8. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients.
Keller C; Kadir A; Forsberg A; Porras O; Nordberg A
J Alzheimers Dis; 2011; 24(1):109-23. PubMed ID: 21157026
[TBL] [Abstract][Full Text] [Related]
10. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment.
Darreh-Shori T; Meurling L; Pettersson T; Hugosson K; Hellström-Lindahl E; Andreasen N; Minthon L; Nordberg A
J Neural Transm (Vienna); 2006 Nov; 113(11):1791-801. PubMed ID: 16868793
[TBL] [Abstract][Full Text] [Related]
11. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
12. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
Darreh-Shori T; Hellström-Lindahl E; Flores-Flores C; Guan ZZ; Soreq H; Nordberg A
J Neurochem; 2004 Mar; 88(5):1102-13. PubMed ID: 15009666
[TBL] [Abstract][Full Text] [Related]
13. The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate.
Unni L; Vicari S; Moriearty P; Schaefer F; Becker R
Methods Find Exp Clin Pharmacol; 2000; 22(1):57-61. PubMed ID: 10791297
[TBL] [Abstract][Full Text] [Related]
14. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease.
Davidsson P; Blennow K; Andreasen N; Eriksson B; Minthon L; Hesse C
Neurosci Lett; 2001 Mar; 300(3):157-60. PubMed ID: 11226635
[TBL] [Abstract][Full Text] [Related]
15. CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer's Disease.
Karami A; Eriksdotter M; Kadir A; Almkvist O; Nordberg A; Darreh-Shori T
Front Mol Neurosci; 2019; 12():239. PubMed ID: 31680850
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Darreh-Shori T; Hosseini SM; Nordberg A
J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
[TBL] [Abstract][Full Text] [Related]
17. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
18. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
[TBL] [Abstract][Full Text] [Related]
19. Functional connectivity increase in the default-mode network of patients with Alzheimer's disease after long-term treatment with Galantamine.
Blautzik J; Keeser D; Paolini M; Kirsch V; Berman A; Coates U; Reiser M; Teipel SJ; Meindl T
Eur Neuropsychopharmacol; 2016 Mar; 26(3):602-13. PubMed ID: 26796681
[TBL] [Abstract][Full Text] [Related]
20. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]